HELP LDL Apheresis Reduces Plasma Pentraxin 3 in Familial Hypercholesterolemia

Background Pentraxin 3 (PTX3), a key component of the humoral arm of innate immunity, is secreted by vascular cells in response to injury, possibly aiming at tuning arterial activation associated with vascular damage. Severe hypercholesterolemia as in familial hypercholesterolemia (FH) promotes vascular inflammation and atherosclerosis; low-density lipoprotein (LDL) apheresis is currently the treatment of choice to reduce plasma lipids in FH. HELP LDL apheresis affects pro- and antiinflammatory biomarkers, however its effects on PTX3 levels are unknown. We assessed the impact of FH and of LDL removal by HELP apheresis on PTX3. Methods Plasma lipids, PTX3, and CRP were measured in 19 patients with FH undergoing chronic HELP LDL apheresis before and after treatment and in 20 control subjects. In the patients assessment of inflammation and oxidative stress markers included also plasma TNFα, fibrinogen and TBARS. Results At baseline, FH patients had higher (p = 0.0002) plasma PTX3 than matched control subjects. In FH PTX3 correlated positively (p≤0.05) with age, gender and CRP and negatively (p = 0.01) with HELP LDL apheresis vintage. The latter association was confirmed after correction for age, gender and CRP. HELP LDL apheresis acutely reduced (p≤0.04) plasma PTX3, CRP, fibrinogen, TBARS and lipids, but not TNFα. No association was observed between mean decrease in PTX3 and in LDL cholesterol. PTX3 paralleled lipids, oxidative stress and inflammation markers in time-course study. Conclusion FH is associated with increased plasma PTX3, which is acutely reduced by HELP LDL apheresis independently of LDL cholesterol, as reflected by the lack of association between change in PTX3 and in LDL levels. These results, together with the finding of a negative relationship between PTX3 and duration of treatment suggest that HELP LDL apheresis may influence both acutely and chronically cardiovascular outcomes in FH by modulating PTX3.

[1]  D. Reda,et al.  Plaque regression and progenitor cell mobilization with intensive lipid elimination regimen (PREMIER) trial design , 2014, Journal of clinical apheresis.

[2]  P. Libby,et al.  Immune effector mechanisms implicated in atherosclerosis: from mice to humans. , 2013, Immunity.

[3]  G. Norata,et al.  The CD1d-Natural Killer T Cell Axis in Atherosclerosis , 2013, Journal of Innate Immunity.

[4]  M. McGowan.  Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol--the role of LDL-apheresis. , 2013, Journal of clinical lipidology.

[5]  C. Garlanda,et al.  The long pentraxin PTX3: a paradigm for humoral pattern recognition molecules , 2013, Annals of the New York Academy of Sciences.

[6]  S. Motor,et al.  Serum Pentraxin 3 Levels Are Associated With the Complexity and Severity of Coronary Artery Disease in Patients With Stable Angina Pectoris , 2013, Journal of Investigative Medicine.

[7]  J. Gallacher,et al.  C-reactive protein, fibrinogen, and cardiovascular disease prediction. , 2012, The New England journal of medicine.

[8]  T. Mollnes,et al.  LDL Apheresis and Inflammation – Implications for Atherosclerosis , 2012, Scandinavian journal of immunology.

[9]  S. Miura,et al.  Plasma pentraxin-3 levels are associated with coronary plaque vulnerability and are decreased by statin , 2012, Coronary artery disease.

[10]  R. Schiel,et al.  LDL-Apheresis: Technical and Clinical Aspects , 2012, TheScientificWorldJournal.

[11]  D. Horstkotte,et al.  HELP apheresis in hypercholesterolemia and cardiovascular disease: efficacy and adverse events after 8,500 procedures , 2012, Clinical Research in Cardiology Supplements.

[12]  E. Pulawski,et al.  Lipid apheresis: oxidative stress, rheology, and vasodilatation , 2012, Clinical Research in Cardiology Supplements.

[13]  Qingbo Xu,et al.  Pentraxin-3 as a Marker of Advanced Atherosclerosis Results from the Bruneck, ARMY and ARFY Studies , 2012, PloS one.

[14]  T. Lehtimäki,et al.  Pentraxin 3 (PTX3) is associated with cardiovascular risk factors: the Health 2000 Survey , 2011, Clinical and experimental immunology.

[15]  K. Berge,et al.  Subjects with Molecularly Defined Familial Hypercholesterolemia or Familial Defective apoB-100 Are Not Being Adequately Treated , 2011, PloS one.

[16]  T. Ueland,et al.  Children with familial hypercholesterolemia are characterized by an inflammatory imbalance between the tumor necrosis factor α system and interleukin-10. , 2011, Atherosclerosis.

[17]  C. Garlanda,et al.  Pentraxins and atherosclerosis: the role of PTX3. , 2011, Current pharmaceutical design.

[18]  L. Hemphill.  NLA Symposium on Familial Hypercholesterolemia Familial hypercholesterolemia : Current treatment options and patient selection for low-density lipoprotein apheresis , 2010 .

[19]  H. Ohbayashi,et al.  Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia. , 2009, Journal of atherosclerosis and thrombosis.

[20]  C. Garlanda,et al.  Deficiency of the Long Pentraxin PTX3 Promotes Vascular Inflammation and Atherosclerosis , 2009, Circulation.

[21]  C. Stefanadis,et al.  Inflammatory and thrombotic processes are associated with vascular dysfunction in children with familial hypercholesterolemia. , 2009, Atherosclerosis.

[22]  T. Kodama,et al.  Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations , 2009, Clinical chemistry and laboratory medicine.

[23]  T. Kodama,et al.  Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions , 2008, The Journal of pathology.

[24]  C. Garlanda,et al.  Long Pentraxin 3, a Key Component of Innate Immunity, Is Modulated by High-Density Lipoproteins in Endothelial Cells , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[25]  G. Biolo,et al.  Relation between the plasma levels of LDL-cholesterol and the expression of the early marker of inflammation long pentraxin PTX3 and the stress response gene p66(ShcA) in pacemaker-implanted patients , 2007, Clinical and Experimental Medicine.

[26]  P. Giral,et al.  Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[27]  Gianni Tognoni,et al.  Prognostic Significance of the Long Pentraxin PTX3 in Acute Myocardial Infarction , 2004, Circulation.

[28]  P. Uberfuhr,et al.  Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins--reduction of circulating proinflammatory and procoagulatory markers. , 2004, Atherosclerosis.

[29]  O. Bezy,et al.  Characterization of the long pentraxin PTX3 as a TNFalpha-induced secreted protein of adipose cells. , 2003, Journal of lipid research.

[30]  M. Matsuzaki,et al.  Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). , 2002, Journal of the American College of Cardiology.

[31]  C. Gibson,et al.  C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. , 2001, Atherosclerosis.

[32]  N. Koga,et al.  Long‐term effects of LDL apheresis on carotid arterial atherosclerosis in familial hypercholesterolaemic patients , 1999, Journal of internal medicine.

[33]  N. Koga.  The retardation of progression, stabilization, and regression of coronary and carotid atherosclerosis by low-density lipoprotein apheresis in patients with familial hypercholesterolemia. , 1997, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[34]  E. Nardon,et al.  Low Density Lipoprotein‐Apheresis Decreases Oxidized Low Density Lipoproteins and Monocyte Adhesion to Endothelial Cells , 1997, ASAIO journal.

[35]  A. Sica,et al.  Characterization of the Promoter for the Human Long Pentraxin PTX3 , 1997, The Journal of Biological Chemistry.

[36]  A. Voss,et al.  Prospective cross‐over comparisons of three low‐density lipoprotein (LDL)‐apheresis methods in patients with familial hypercholesterolaemia , 1996, European journal of clinical investigation.

[37]  M. Shinomiya,et al.  Evaluation of double filtration plasmapheresis, thermofiltration, and low-density lipoprotein adsorptive methods by crossover test in the treatment of familial hypercholesterolemia patients. , 1996, Artificial organs.